Healthcare Industry News: migraine
News Release - November 1, 2007
Stephen J. Peroutka, M.D., Ph.D. Joins Zogenix as Chief Medical OfficerSAN DIEGO--(HSMN NewsFeed)--Zogenix, Inc., a privately held neuroscience-focused specialty pharmaceutical company, announced today that Stephen J. Peroutka, M.D., Ph.D. has joined the company in the role of Chief Medical Officer.
Dr. Peroutka is a neurologist and pharmacologist whose research and professional experience in neuroscience spans twenty-five years. Dr. Peroutka received his M.D. and Ph.D. degrees in 1979 and 1980, respectively, from the Johns Hopkins University School of Medicine. After completing an internship at Stanford in 1981 and a residency at Johns Hopkins Hospital, he was an Assistant Professor of Neurology and Pharmacology at Stanford from 1984-1990 and was Chief, Neurology Service, at the Palo Alto VA Hospital from 1988-1990.
In 1990, he joined Genentech, Inc. where he established the Department of Neuroscience and became its first Director in 1991. In 1993, he founded Spectra Biomedical, Inc., an association genetics company focused on migraine. In June, 1997, Spectra Biomedical, Inc. was acquired by Glaxo Wellcome Inc. Subsequently, he has been an independent consultant to the pharmaceutical and biotechnology industries. He was Chief Medical Officer at Collabra Pharma in 2000-2001, Vice President of Clinical Research at Deltagen, Inc. in 2001-2002 and President and CEO of Synergia Pharma, Inc. from 2003-2005. Most recently, he was the Franchise Development Leader for Pain at Johnson & Johnson.
“Having Steve join our management team is highly significant for Zogenix,” said Stephen Farr, Ph.D., President and COO. “His scientific, clinical and business experience, particularly in the areas of migraine and pain, will be invaluable as we continue to build our pipeline and move into the commercialization phase with our first product, sumatriptan Intraject®.”
About Zogenix, Inc.
Zogenix, Inc., with offices in Emeryville and San Diego, CA, is a private, specialty pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The company's initial focus is the completion of the late-stage development and commercialization of sumatriptan Intraject – a needle-free, single-use, disposable, and easy-to-use subcutaneous delivery system for sumatriptan that will compete in the $2.7 billion triptan segment of the migraine market. The company also plans to license the patented Intraject drug delivery system to other companies. For additional information, visit www.zogenix.com.
Intraject is a registered trademark of Zogenix, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.